Acellular Pro-inflammatory Preparations for Immune Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches fail to effectively induce a pro-inflammatory state or immune stimulation, particularly in conditions associated with decreased or inappropriate immune responses such as cancer and infections, due to limited specificity and effectiveness of cytotoxic drugs and the inability to adequately stimulate a pro-inflammatory response.
Innovation Solution
Development of acellular pro-inflammatory preparations derived from allogeneic leukocyte populations, which are contacted under conditions to allow pro-inflammatory allo-recognition, with the resulting miRNA-enriched components being purified and formulated for administration to induce a therapeutic immune stimulation by altering the ratio of regulatory T cells to pro-inflammatory T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If chemical cytotoxic agents are used to target proliferating cells, then cancer cells are preferentially affected due to their higher mitotic rate, but the treatment lacks direct specificity towards the cancer cells
Solution Approach 1:
The patent extracts and isolates specific miRNA species from allogeneic leukocytes that are responsible for inducing pro-inflammatory immune responses. These purified miRNA components are then administered therapeutically to induce immune stimulation against cancer cells, achieving targeted effect without using complex cytotoxic agents
Solution Approach 2:
The patent uses miRNA species as intermediary molecules that mediate the immune response between the administered preparation and the cancer cells. These miRNA act as signaling molecules that trigger the patient's immune system to recognize and attack tumor cells, providing indirect but specific targeting
2Reliability
If clonal expansion of reactive leukocytes is induced to achieve target cell antigen-specific response, then the desired pro-inflammatory state may be stimulated, but the approach is expensive and complex
Solution Approach 1:
The patent uses stable, isolated miRNA species that can be produced once and stored for repeated administrations. These miRNA preparations replace complex, expensive in vivo clonal expansion protocols with simpler, more cost-effective molecular therapies that achieve similar or superior immune stimulation effects
Solution Approach 2:
The patent performs preliminary isolation and characterization of specific miRNA species from allogeneic leukocytes before therapeutic administration. This pre-preparation of active immune-stimulating components allows for standardized, reproducible treatments without requiring complex in vivo manipulation of entire leukocyte populations
3Reliability
If the immune system is suppressed by regulatory T cells, then immune tolerance is maintained, but this prevents effective response to infections and cancer
Solution Approach 1:
The patent administers miRNA-enriched preparations that preemptively counteract the suppressive effects of regulatory T cells by inducing pro-inflammatory immune responses. The miRNA species prepare the immune system in advance to overcome Treg-mediated suppression and mount effective anti-tumor and anti-infective responses
Data Source
Figure 1A~1B
Figure 1C
Figure 2A
AI summary
This invention relates to acellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated. The leukocyte populations are contacted so as to allow pro-inflammatory allo- recognition. Acellular-based preparations and processes for achieving therapy are also provided.